Dopamine receptor imaging after dopamine depletion in adults who are at "ultra high risk" for psychosis, and in healthy volunteers: a (123I)IBZM SPECT study

Dopamine receptor imaging after dopamine depletion in adults who are at "ultra high risk" for psychosis, and in healthy volunteers: a (123I)IBZM SPECT study - Identifying dopaminergic markers for prediction of psychosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30735

Enrollment

Registered

2007-04-23

Start date

2007-04-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delusion psychosis

Interventions

Temporary acute dopamine depletion with alpha-metyrosine (AMPT)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a) 40 patients: - age 18 till 35 years - "ultra high risk" criteria for development of psychosis, as defined by McGorry et al. (2002) Healthy controls: - Matched for age, sex, ethnicity and IQ

Exclusion criteria

Exclusion criteria: - previous psychotic episode for more than one week - previous use of antipsychotics, amphetamine or cocaine - medical disorder affecting brain function e.g. epilepsy - participation in investigations with radio-activity in the last year - pregnancy

Design outcomes

Primary

Measure	Time frame
The main outcome measure will be the difference in (123I)IBZM striatal dopamine (D2) binding between the control scan and the scan with acute dopamine depletion with AMPT.	—

Secondary

Measure	Time frame
1. Level of catecholamin synthesis, measured by blood levels of: - homovanillin acid (HVA) - 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) - prolactin and urine levels of: - HVA - MHPG - dopamin (free and conjugated) en norepinephrin (free and conjugated) 2. Possible extrapyramidal side-effects 3. Subjective experiences 4. Depressive and positive and negative symptoms 5. Pre pulse inhibition (PPI): a non-invasive electrophysiological measurement during 12 minutes. The eye blink reflex will be measured while the person listens to beep tones with a headphone.	—

Measure

Time frame

1. Level of catecholamin synthesis, measured by blood levels of: - homovanillin acid (HVA) - 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) - prolactin and urine levels of: - HVA - MHPG - dopamin (free and conjugated) en norepinephrin (free and conjugated) 2. Possible extrapyramidal side-effects 3. Subjective experiences 4. Depressive and positive and negative symptoms 5. Pre pulse inhibition (PPI): a non-invasive electrophysiological measurement during 12 minutes. The eye blink reflex will be measured while the person listens to beep tones with a headphone.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)